Table 2.

Levels of Complement Activation Products and Cytokines in the Aqueous Humor of Patients with CNV and in Controls

	Eyes with CNV
Analyte	PNV (n = 25) Median (IQR)	PCV (n = 23) Median (IQR)	Drusen-Associated nAMD (n = 24) Median (IQR)	P * [Statistical Power†]	Total (N = 72)Median (IQR)	Controls (n = 33) Median (IQR)	P ‡ [Statistical Power§]
C3a (ng/mL)	2.34 (1.97–2.94)	3.12 (2.21–3.48)	2.95 (2.36–3.57)	0.035 [0.65]	2.7 (2.14–3.35)	2.2 (1.52–2.82)	0.004 [0.83]
C4a (ng/mL)	1.47 (1.21–1.80)	1.77 (1.48–2.08)	1.97 (1.41–2.43)	0.046 [0.58]	1.69 (1.35–2.09)	1.48 (1.03–1.92)	0.11 [0.48]
C5a (ng/mL)	0.018 (0.010–0.021)	0.017 (0.009–0.031)	0.027 (0.012–0.067)	0.25 [0.50]	0.018 (0.010–0.033)	0.032 (0.015–0.056)	0.049 [0.18]
VEGF (pg/mL)	42.0 (26.3–53.2)	40.4 (27.3–67.8)	38.6 (28.5–49.1)	0.79 [0.18]	40.1 (27.3–52.6)	25.3 (17.1–36.0)	0.001 [0.80]
MCP-1 (pg/mL)	273.9 (188.1–371.4)	306.7 (246.7–427.4)	311.9 (242.6–618.0)	0.24 [0.47]	305.8 (221.4–423.1)	201.3 (122.4–305.5)	0.001 [0.83]

^*Kruskal–Wallis test among CNV subtypes.

^†Statistical power among the three categories.

^‡Mann–Whitney U test between the eyes with CNV and controls.

^§Statistical power between total eyes with CNV and controls.